

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2008 (21.02.2008)

PCT

(10) International Publication Number
WO 2008/021353 A2

(51) International Patent Classification:
A61K 39/42 (2006.01)

(21) International Application Number:

PCT/US2007/017970

(22) International Filing Date: 14 August 2007 (14.08.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/822,354 14 August 2006 (14.08.2006) US

(71) Applicant and

(72) Inventor: LUO, Guangxiang [—/US]; 2456 Olde Bridge Lane, Lexington, KY 40513 (US).

(74) Agent: TANKHA, Ashok; Of Counsel, Lipton, Weinberger & Husick, 36 Greenleigh Drive, Sewell, NJ 08080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: COMPOSITION AND METHOD FOR CONTROLLING HEPATITIS C VIRUS INFECTION

(57) Abstract: Disclosed herein are methods and compositions for the treatment and prevention of Hepatitis C Virus (HCV) infection and methods of screening for antiviral agents against HCV infection and/or production. A method of using compositions of certain apolipoprotein-specific monoclonal or polyclonal antibodies to inhibit HCV infectivity is disclosed. Further, methods of using small interfering RNAs (siRNAs) specific to apolipoproteins for treating and/or preventing HCV infection are disclosed. Also disclosed are methods of using siRNAs specific and/or small molecule inhibitors to certain lipoprotein biosynthetic genes and of using recombinant apolipoprotein E and/or their forms of lipoproteins to treat and/or prevent HCV infections. Screening methods for anti-HCV agents include assessing the effect of a candidate agent on apolipoprotein E and/or apolipoprotein C-I gene expression, assembly, and/or secretion and assessing the effect of a candidate agent on the blockage of the interaction and/or incorporation of HCV nonstructural proteins and/or their fusion forms with reporter proteins into HCV virions.



WO 2008/021353 A2

COMPOSITION AND METHOD FOR CONTROLLING HEPATITIS C VIRUS INFECTION

This application claims the benefit of provisional application no. 60/822,354 titled
“Composition And Methods For Treating And Preventing Hepatitis C Virus Infection and
5 Screening Methods For Identifying Anti-Hepatitis C Virus Agents” filed Aug. 14, 2006.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Research for this invention was made with support from the NCI, Grant Number
CA093712, and the NIAID, Grant Number AI51592.

10

FIELD OF THE INVENTION

The present invention relates to the treatment and prevention of Hepatitis C Virus (HCV)
infection and screening for antiviral agents against HCV infection and/or production.

15 BACKGROUND OF THE INVENTION

The hepatitis C virus (HCV) was discovered in 1989 by molecular cloning and has since
been recognized as a major cause of viral hepatitis in humans. HCV is a single-stranded positive-
sense RNA virus, which is about 9.6 kb in length. HCV belongs to the *Hepacivirus* genus of the
family *Flaviviridae*. The viral RNA genome consists of the 5' untranslated region (5'UTR), a
20 single open reading frame (ORF) encoding a viral polypeptide of 3,010-3,040 amino acids, and
the 3' untranslated region (3'UTR) of variable length. Upon translation, the viral polyprotein is
cleaved by cellular peptidases and viral proteases into core (C), envelope glycoproteins (E1 and
E2), P7, non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B. Sequence
analysis and comparison studies have revealed that both the 5'UTR and 3'UTR of the HCV
25 genome are highly conserved. In contrast, sequences of the ORF exhibit a variation among HCV
isolates. Based on the nucleotide sequence similarity, HCV has been further grouped into six
major genotypes and numerous subtypes.

HCV infection is characterized by the establishment of chronic infection in up to about
30 85% of individuals exposed to HCV. The chronic HCV infection carries an increased risk of
developing fatal liver diseases such as cirrhosis, liver failure, and hepatocellular carcinoma.

HCV-associated end-stage liver disease is the leading cause of liver transplantation in the United States (US). It is estimated that approximately 4 million people in the US and 170 million people worldwide are persistently infected with HCV. Each year, HCV infection results in 8,000-10,000 deaths in the US alone. HCV-related deaths are expected to triple within the next 10-20 years if
5 no effective intervention is made available. Currently, there is no specific and effective therapy to treat HCV infection. Accordingly, there remains an urgent need in the art for specific antiviral targets and agents for effectively treating and preventing HCV infection.

The structure and biochemical compositions of HCV virions have not been determined,
10 although certain studies have found that HCV virions isolated from the plasma of hepatitis C patients were associated with lipoproteins to form lipovirions (LVPs). Apolipoproteins B and E were detected in the low-density fractions of HCV RNA-containing particles, which could also be captured by apolipoprotein-specific antibodies, suggesting an association of the low-density HCV virions with human lipoproteins. However, the roles of apolipoproteins in HCV
15 assembly and production have not been defined.

SUMMARY OF THE INVENTION

The present invention addresses the above identified problems, and others, by providing
20 compositions and methods for treating and/or preventing hepatitis C virus infection in humans. The present invention further includes targets and methods for identification (screening) of effective anti-HCV agents.

The present invention discloses a method of using compositions of apoE- and/or apoC-I-
25 specific monoclonal or polyclonal antibodies to inhibit HCV infectivity. The method further comprises the step of administering an effective amount of the composition to a patient.

The present invention discloses methods of using siRNAs specific to apolipoproteins, for
30 treating and/or preventing HCV infection. The present invention further includes siRNAs specific for certain lipoprotein biosynthetic genes for treating and/or preventing HCV infection.

Also disclosed is a method of using recombinant apoE (E2, E3, and E4) protein and/or their forms of lipoproteins to treat and/or prevent HCV infections.

The present invention further discloses a method of screening for anti-HCV agents by assessing the effect of a candidate agent on apoE and/or apoC-I gene expression, assembly, and/or secretion. The present invention also includes a method of screening for anti-HCV agents by assessing the effect of a candidate agent on the blockage of the interaction and/or incorporation of HCV nonstructural proteins and/or their fusion forms with reporter proteins into HCV virions.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of the embodiments, is better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, exemplary illustrations of the invention are shown in the drawings. However, the invention is not limited to the specific methods disclosed herein.

FIGURE 1 is a flow chart illustrating an exemplary method for preventing and/or treating Hepatitis C virus (HCV) infection in accordance with the present invention.

FIGURE 2 is a flow chart illustrating an exemplary method of screening for anti-HCV agents in accordance with the present invention.

FIGURE 3A depicts the results of HCV virion RNA (vRNA) determined by a ribonuclease (RNase) protection assay (RPA) in a sucrose gradient sedimentation analysis of HCV virions in culture media and densities (g/ml) of each fraction.

FIGURE 3B is a Western blot analysis of HCV NS3 protein in cells infected with the different fractions identified in **FIGURE 3A**.

FIGURE 3C depicts the results of RPA used to determine positive-strand HCV RNA in cells infected with the different fractions identified in **FIGURE 3A**.

FIGURE 3D is a Western blot analysis of apolipoproteins B100 (apoB100), C-I (apoC-I), and E (apoE), wherein a density gradient sedimentation analysis of HCV RNA-containing particles is performed as shown in **FIGURE 3A**, and apoB100, apoC-I, and apoE proteins were detected by using apoB-, apoC-I- and apoE-specific antibodies.

FIGURE 4A depicts the results of a study carried out to determine the HCV-neutralizing activity of apoE-specific monoclonal antibodies, where HCV positive-strand RNA levels in the Huh7.5 cells infected with HCV in the presence of apoE-specific monoclonal antibodies were determined by RPA.

FIGURE 4B is a graph showing the correlation between HCV-neutralizing activity and concentrations of apoE-specific monoclonal antibodies using the quantitative data derived from **FIGURE 4A**.

FIGURE 4C shows the reduction of infectious HCV titers in the cell culture supernatant of Huh7.5 cells that were infected with HCV in the presence of apoE-specific monoclonal antibodies. The infectious HCV titers were determined by immunofluorescence assay (IFA) as foci-forming units per milliliter (ffu/ml) of cell culture supernatant.

FIGURE 4D depicts the results of an analysis of the inhibition of HCV infectivity in the infectious fractions 3 to 5 of the sedimentation analysis as shown in **FIGURES 3B and 3C** by HCV E2- and ApoE-specific monoclonal antibodies.

FIGURE 5 shows the reduction of HCV infectivity by an apoC-I polyclonal antibody, as determined by Western blot analysis of HCV NS3 protein in cells infected with HCV in the presence of increasing concentrations of apoC-I polyclonal antibody.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.